Radically different
Category Added in a WPeMatico Campaign
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here.
Yesterday, my friend who lives in the Bay Area told me that I should be asking people about their peptide “stack,” which is where someone takes multiple peptides for presumably greater health benefit.
Amid rising concern over efforts to contain HIV, Merck has reached voluntary licensing deals with seven companies to make generic versions of an experimental, once-a-month prevention pill in 129 low- and middle-income countries.
The agreements will allow the manufacturers — three of which are based in Africa and four in India — to sell generic versions to both public and private buyers, which is designed to ensure the medicine becomes available to the widest possible population. Moreover, the deals are royalty free, which makes it easier for the generic companies to predict costs.
The timing of the announcement is notable because Merck is striking these deals while its medicine, known as alimatravir, is currently undergoing a pair of late-stage clinical trials. By doing so now, the company believes it will help the generic makers plan for wide-scale production and the necessary steps to receive regulatory approvals around the world.
Researchers in Japan have identified a compound that could help muscles stay strong as we age. Preclinical results published today in Scientific Reports uncover a promising new approach to treat conditions causing muscle loss and may help people preserve independence and quality of life in their later years.
Skeletal muscle is essential for movement, accounting for approximately 40% of an adult’s total body weight. Yet it is also one of the first tissues to decline with age, progressively leading to weakness, scarring, fat accumulation, and loss of fast-twitch muscle fibers.
The study focused on hepatocyte growth factor (HGF), a molecule that plays a crucial role in activating the repair of muscle fibers. In healthy muscle, this molecule is present in the tissue surrounding muscle fibers. When the muscle is injured or stimulated through exercise, HGF is released and binds to c-met receptors on stem cells within the skeletal muscle, known as satellite cells. This activates the satellite cells and enables them to proliferate and differentiate to repair muscle fibers.
Aging can interfere with this process, making it a key driver of age-related muscle wasting. In an earlier study, the same team found that aging causes HGF to undergo nitration, a chemical modification that prevents it from binding to c-met receptors.
“HGF is not necessarily missing as we age,” said Ryuichi Tatsumi, PhD, professor at Kyushu University. “Rather, it can be chemically altered after it is made. That led us to wonder whether a compound with strong antioxidant capacity might protect HGF, either by preventing nitration or by compensating for the functional loss it causes.”
Tatsumi’s team then identified two compounds with strong antioxidant activity that could potentially interfere with HGF nitration: glutathione trisulfide (GSSSG) and lipoic acid trisulfide (LASSS). Both belong to a drug class known as trisulfides that has been gaining attention in preclinical research for their protective and anti-inflammatory properties across a wide range of indications.
While both drugs were able to suppress HGF nitration, only LASSS restored its ability to bind to c-met receptors. In fact, the drug candidate more than doubled HGF’s binding affinity while simultaneously preventing nitration.
“This exceeded our expectations,” said Tatsumi. “We knew trisulfides had diverse biological functions, but we never expected that simply mixing HGF with LASSS would produce such a striking effect. What this tells us is that LASSS does more than simply neutralize reactive molecules. It may interact directly with HGF and induce a subtle structural change, creating an enhanced ‘Super HGF’ form that binds c-met more strongly and resists nitration.”
The researchers then tested these effects in a mouse model of muscle atrophy. Compared to untreated animals, mice receiving LASSS showed a significant reduction in HGF nitration. Although further preclinical studies are needed before this approach can be tested in humans, these early findings point toward a promising strategy to preserve the muscle’s natural regenerative capacity and support healthy aging.
The post Drug Candidate Combats Age-Related Muscle Loss appeared first on Inside Precision Medicine.
In 2025, there were 216 active drug shortages in the U.S., impacting Americans’ access to lifesaving medications. The resilience of our pharmaceuticals supply chains has been increasingly framed as a national security issue, including by the White House — and rightly so, as Covid-19 magnified the massive costs of a health system ill-equipped to care for its population.
But this national security framing has heavily skewed toward a U.S.-China competition lens, distracting from the real root causes of our pharmaceuticals supply chain vulnerabilities: inadequate regulation of an industry that tends to prioritize profit over America’s health.
Amid debates over whether the political influence of the Make America Healthy Again movement is on the wane, a new bill advanced in the Senate on Wednesday shows that concerns over ultra-processed food continue to upend the usual partisan stances in Washington.
The bill, which would ban junk food advertisements targeted to children and require the Food and Drug Administration to put strong warning labels on ultra-processed foods high in sugar, salt, and saturated fat, was proposed by Sen. Bernie Sanders (I-Vt.).
For 18 months, the Trump administration has been accused by science advocates of shredding a social contract between academic researchers and the federal government that made the United States the world’s most powerful engine of discovery. Now it’s proposing a way to rebuild American science.
Taking inspiration from “Science — The Endless Frontier,” a 1945 manifesto that became the blueprint for the rise of American research universities, Trump’s science adviser, Michael Kratsios, this week put forth his version of such a report. Called “Science: A New Golden Age” and drafted by the White House Office of Science and Technology Policy, it calls for shifting hundreds of billions of research dollars from universities to industry, primarily tech and artificial intelligence companies.
The report acknowledges problems scientists have long attempted to grapple with, but advocates and scientists expressed concern that the report’s espoused goal of improving science is being undermined by other administration actions, chiefly the grievances expressed by President Trump and his aides against immigration, universities, and programs that they deem as promoting diversity, equity, and inclusion.